XML 13 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Mar. 20, 2025
Jun. 28, 2024
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2024    
Entity Registrant Name PRECISION BIOSCIENCES INC    
Entity Central Index Key 0001357874    
Trading Symbol DTIL    
Current Fiscal Year End Date --12-31    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Common Stock, Shares Outstanding   10,481,931  
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity File Number 001-38841    
Entity Tax Identification Number 20-4206017    
Entity Address, Address Line One 302 East Pettigrew St.    
Entity Address, Address Line Two Suite A-100    
Entity Address, City or Town Durham    
Entity Address, State or Province NC    
Entity Address, Postal Zip Code 27701    
City Area Code 919    
Local Phone Number 314-5512    
Title of 12(b) Security Common Stock, par value $0.000005 per share    
Security Exchange Name NASDAQ    
Entity Incorporation, State or Country Code DE    
Document Annual Report true    
Document Transition Report false    
Entity Voluntary Filers No    
Entity Well-known Seasoned Issuer No    
Entity Public Float     $ 66.8
Documents Incorporated by Reference

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant’s definitive proxy statement for its 2025 annual stockholders’ meeting, which is to be filed within 120 days of the registrant’s fiscal year ended December 31, 2024, are incorporated by reference into Part III of this Annual Report on Form 10-K.

    
Auditor Name Deloitte & Touche LLP    
Auditor Firm ID 34    
Auditor Location Raleigh, North Carolina    
Auditor Opinion [Text Block]

We have audited the accompanying balance sheets of Precision BioSciences, Inc. (the “Company”) as of December 31, 2024 and 2023, the related statements of operations, changes in stockholders’ equity, and cash flows, for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.